Chemical inhibitors of MRVI1 act primarily by targeting the Rho-associated protein kinase (ROCK) pathway, which is a critical regulator of the actin cytoskeleton. The selective inhibition of ROCK by compounds such as Y-27632, Fasudil (also known as HA-1077), Hydroxyfasudil, H-1152, Thiazovivin, Glycyl-H-1152, Ripasudil, RKI-1447, and GSK429286A can lead to the attenuation of MRVI1's role in cellular processes. Y-27632, for instance, is known for its ability to prevent stress fiber formation, thereby indirectly inhibiting the function of MRVI1 in maintaining cellular structure and contraction. Fasudil and its metabolite Hydroxyfasudil operate by suppressing the phosphorylation of myosin light chains, which is a downstream effect of MRVI1 activity. By reducing the activation of myosin light chain phosphatase, these inhibitors limit MRVI1's role in smooth muscle contraction. H-1152 and its analog Glycyl-H-1152 offer a more potent inhibition of ROCK, leading to a more substantial reduction in MRVI1-mediated stress fiber formation and cellular contraction.
In addition to these compounds, Thiazovivin contributes to the inhibition of ROCK, enhancing cell survival and potentially affecting MRVI1's role in apoptosis. Ripasudil, which is also a ROCK inhibitor, modifies the downstream functions that are associated with MRVI1, particularly in the context of vascular tension and remodeling. RKI-1447, a strong inhibitor of both ROCK1 and ROCK2, can stabilize the actin cytoskeleton, which in turn affects the cellular changes typically mediated by MRVI1 via the RhoA/ROCK pathway. GSK429286A, as a selective ROCK1 inhibitor, also contributes to the downregulation of the effects of ROCK activation, impacting the modulation of the actin cytoskeleton and cellular contraction where MRVI1 is involved. Lastly, while not directly influencing the ROCK pathway, SR 7826 targets LIM kinase, which is involved in actin polymerization. By inhibiting LIM kinase, SR 7826 can alter the dynamics of actin polymerization and depolymerization, which are essential to MRVI1-mediated cellular functions. These chemicals collectively contribute to the modulation of MRVI1 activity by influencing the actin cytoskeleton and associated cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of ROCK (Rho-associated protein kinase), which directly interacts with MRVI1 in smooth muscle cells and other cell types. Since MRVI1 is involved in actin cytoskeleton reorganization, Y-27632 inhibits ROCK, which is essential for stress fiber formation and thus inhibits MRVI1's role in cellular structure maintenance and contraction. | ||||||
Fasudil, Monohydrochloride Salt | 105628-07-7 | sc-203418 sc-203418A sc-203418B sc-203418C sc-203418D sc-203418E sc-203418F | 10 mg 50 mg 250 mg 1 g 2 g 5 g 10 g | $18.00 $33.00 $87.00 $168.00 $253.00 $496.00 $910.00 | 5 | |
Fasudil, another ROCK inhibitor, can suppress the phosphorylation of myosin light chains, which is a downstream effect mediated by MRVI1 activity. By inhibiting ROCK, Fasudil prevents the activation of myosin light chain phosphatase, thereby limiting the functional activity of MRVI1 in smooth muscle contraction and vasodilation. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
H-1152 is a more potent inhibitor of ROCK than Y-27632 and Fasudil, thus it also indirectly inhibits MRVI1 by preventing RhoA/ROCK pathway-mediated stress fiber formation and cellular contraction processes where MRVI1 is involved. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
Thiazovivin is a ROCK inhibitor that can prevent apoptosis and enhance cell survival. While it is often used to promote stem cell survival, its inhibition of ROCK also impacts the actin cytoskeleton and cellular tension environment where MRVI1 is active. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
RKI-1447 is a strong inhibitor of ROCK1 and ROCK2, which indirectly inhibits MRVI1 activity by stabilizing the actin cytoskeleton and preventing the cellular changes typically mediated by MRVI1 through the RhoA/ROCK pathway. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
GSK429286A is a selective ROCK1 inhibitor that can indirectly inhibit MRVI1 by reducing the downstream effects of ROCK activation, which include modulation of the actin cytoskeleton and cellular contraction, processes in which MRVI1 is implicated. | ||||||